Rafferty Asset Management Portfolio holdings
AUM
$30.3B
1-Year Return
18.89%
This Quarter Return
+7.65%
1 Year Return
+18.89%
3 Year Return
+101.02%
5 Year Return
+164.75%
10 Year Return
+314.44%
AUM
$8.27B
AUM Growth
+$1.17B
(+17%)
Cap. Flow
+$750M
Cap. Flow
% of AUM
9.07%
Top 10 Holdings %
Top 10 Hldgs %
43.67%
Holding
1,071
New
101
Increased
574
Reduced
272
Closed
122
Top Buys
| 1 |
VanEck Gold Miners ETF
GDX
|
$287M |
| 2 |
VanEck Junior Gold Miners ETF
GDXJ
|
$258M |
| 3 |
Apple
AAPL
|
$67.9M |
| 4 |
Microsoft
MSFT
|
$62.7M |
| 5 |
iShares China Large-Cap ETF
FXI
|
$59.7M |
Top Sells
| 1 |
iShares Russell 2000 ETF
IWM
|
$189M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
$112M |
| 3 |
Visa
V
|
$56.8M |
| 4 |
Mastercard
MA
|
$50M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
$42.1M |
Sector Composition
| 1 | Technology | 27.51% |
| 2 | Financials | 14.83% |
| 3 | Healthcare | 4.08% |
| 4 | Consumer Discretionary | 3.56% |
| 5 | Industrials | 3.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Novavax
NVAX
$1.28B
| $2.25M | 0.03% |
20,788
-170
| -0.8% | -$18.4K |
|
377
Insmed
INSM
$30.7B
| $2.24M | 0.03% |
69,685
+34,564
| +98% | +$1.11M |
|
378
Western Alliance Bancorporation
WAL
$10B
| $2.24M | 0.03% |
70,773
+11,060
| +19% | +$350K |
|
379
Acadia Pharmaceuticals
ACAD
$4.26B
| $2.24M | 0.03% |
54,181
+33,346
| +160% | +$1.38M |
|
380
Exelixis
EXEL
$10.2B
| $2.23M | 0.03% |
91,309
+27,955
| +44% | +$684K |
|
381
Lincoln National
LNC
$7.98B
| $2.22M | 0.03% |
70,712
+20,579
| +41% | +$645K |
|
382
Ultragenyx Pharmaceutical
RARE
$3.07B
| $2.21M | 0.03% |
26,873
+12,840
| +91% | +$1.06M |
|
383
Tyler Technologies
TYL
$24.2B
| $2.21M | 0.03% |
6,338
+1,603
| +34% | +$559K |
|
384
Arcturus Therapeutics
ARCT
$485M
| $2.21M | 0.03% |
+51,404
| New | +$2.21M |
|
|
BLUE
385
DELISTED
bluebird bio
BLUE
| $2.2M | 0.03% |
3,153
+1,999
| +173% | +$1.4M |
|
|
TPTX
386
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $2.2M | 0.03% |
25,209
+15,116
| +150% | +$1.32M |
|
387
Popular Inc
BPOP
$8.47B
| $2.2M | 0.03% |
60,623
+7,824
| +15% | +$284K |
|
388
M/I Homes
MHO
$4.14B
| $2.2M | 0.03% |
47,725
+7,264
| +18% | +$335K |
|
389
Arista Networks
ANET
$180B
| $2.19M | 0.03% |
169,408
+48,688
| +40% | +$630K |
|
|
DCPH
390
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $2.19M | 0.03% |
42,630
+25,012
| +142% | +$1.28M |
|
|
BHVN
391
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $2.19M | 0.03% |
33,608
+19,137
| +132% | +$1.24M |
|
392
Suburban Propane Partners
SPH
$1.2B
| $2.18M | 0.03% |
133,913
+34,878
| +35% | +$568K |
|
|
SAGE
393
DELISTED
Sage Therapeutics
SAGE
| $2.18M | 0.03% |
35,603
+9,224
| +35% | +$564K |
|
394
Amicus Therapeutics
FOLD
$2.46B
| $2.17M | 0.03% |
153,931
+66,546
| +76% | +$940K |
|
395
Brookfield Renewable
BEP
$7.06B
| $2.17M | 0.03% |
61,814
+580
| +0.9% | +$20.3K |
|
396
Zebra Technologies
ZBRA
$16B
| $2.14M | 0.03% |
8,464
+2,140
| +34% | +$540K |
|
397
Sarepta Therapeutics
SRPT
$1.96B
| $2.13M | 0.03% |
15,181
+9,109
| +150% | +$1.28M |
|
398
TG Therapeutics
TGTX
$5.11B
| $2.13M | 0.03% |
79,653
+24,096
| +43% | +$645K |
|
399
Builders FirstSource
BLDR
$16.5B
| $2.09M | 0.03% |
64,154
+9,358
| +17% | +$305K |
|
400
Emergent Biosolutions
EBS
$404M
| $2.09M | 0.03% |
20,231
+3,754
| +23% | +$388K |
|